Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BGB-A445 + Tislelizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BGB-A445||BGB A445|BGBA445||OX40 Antibody 13||BGB-A445 is an activating anti-TNFRSF4 (OX40) antibody that does not block binding to its ligand, OX40L, potentially resulting in increased immune response and anti-tumor activity (Journal for ImmunoTherapy of Cancer 2020;8:699).|
|Tislelizumab||BGB-A317||Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98||Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04215978||Phase I||BGB-A445 + Tislelizumab BGB-A445||Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors||Recruiting||USA||3|